# Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')2-Modified Graphene Field-Effect Biosensor.

- **DOI:** [10.1002/smll.73928](https://doi.org/10.1002/smll.73928)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** F(ab')2 functionalization improves GFET detection of NfL in diluted plasma, but five clinical samples cannot establish diagnostic validation.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1002%2Fsmll.73928

## Key claims

1. Compared with whole antibody-based GFETs, this F(ab')2-modified GFET platform is shown to achieve a 114% increase in sensitivity, a fivefold improvement in the limit-of-detection down to 0.18 pg/mL.
   - Support: Supported
   - Type: Primary finding
   - Basis: direct IgG comparison supports the direction, but diluted-matrix calibration and incomplete independent-unit accounting limit certainty
   - Location: Abstract; Results, Performance of GFET Devices, Figure 4B
2. This biosensing platform is validated against Simoa technology for the detection of NfL in clinical plasma samples, yielding a high correlation coefficient of 0.99.
   - Support: Tentative
   - Type: Secondary
   - Basis: five samples, correlation without agreement analysis, and 123% recovery cannot establish clinical validation
   - Location: Abstract; Results, Clinical Sample Measurements with GFET and Simoa, Figure 5B–C
3. This work utilizes smaller antibody fragments F(ab')2 to mitigate Debye screening and enhance sensing performance.
   - Support: Tentative
   - Type: Secondary
   - Basis: the fragment advantage appears only in highly diluted media and disappears at higher ionic strength
   - Location: Abstract; Results, Performance of GFET Devices, Figure 4C
4. At 0.001x and 0.01x PBS, F(ab')2 aNfL-immobilized GFETs exhibited significantly greater responses compared to their IgG counterparts.
   - Support: Supported
   - Type: Secondary
   - Basis: a direct fixed-concentration ionic-strength comparison supports the stated result under the tested conditions
   - Location: Results, Performance of GFET Devices, Figure 4C

## Strengths

- **Direct fragment-versus-IgG analytical comparison** F(ab')2 and whole-IgG GFETs are compared across the same concentration range, with reported improvements in slope, LoD, and variability. The ionic-strength series further tests when the fragment advantage appears.
  - Dimension: methodological rigour
  - Location: Results, Performance of GFET Devices, Figure 4B–C
- **Orthogonal surface chemistry characterization** PBASE adsorption and density are assessed through Raman spectroscopy, XPS, AFM, QCM-D, and transfer-curve analysis. QCM-D, electrical, and XPS estimates converge within a relatively narrow range.
  - Dimension: contribution
  - Location: Results, Molecular Density of PBASE, Figure 2
- **Material limitations are explicitly identified** The paper states that physiological ionic strength requires additional mitigation and that five clinical samples cannot establish clinical performance. These acknowledgements define relevant next steps even though the final claims remain too broad.
  - Dimension: positioning
  - Location: Results, Figure 4C; Results, Clinical Sample Measurements with GFET and Simoa

## Limitations

- **Clinical validation rests on five samples** The clinical comparison includes five moderate-to-severe TBI plasma samples and reports Pearson correlation rather than an agreement analysis. Mean recovery of 123% also indicates systematic cross-platform difference that correlation alone does not resolve.
  - Dimension: methodological rigour
  - Location: Results, Clinical Sample Measurements with GFET and Simoa, Figure 5B–C
- **Deployment language exceeds demonstrated conditions** The Abstract and Conclusions present broad point-of-care, diagnostic, and prognostic potential, while samples are diluted 100-fold and the F(ab')2 advantage is absent at 0.1× and 1× PBS.
  - Dimension: reporting
  - Location: Abstract; Results, Performance of GFET Devices, Figure 4C; Conclusions
- **Transferability remains largely untested** Testing is confined to one platform and narrow clinical cohort, with reported device-to-device mobility variation near 20% and only two weeks of refrigerated stability evidence.
  - Dimension: application pathway
  - Location: Results, Performance of GFET Devices, Figure 4D–F

## Reliability checks

No concerns (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Clean. No reporting or research-conduct concern supported by the supplied text was raised.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean
  - 59 references in manuscript
  - 59 of 59 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
